A concerning program by Eli Lilly ties increased copay assistance for one of its top-selling brand-name drugs, tirzepatide (Zepbound), to having a prescription for another, ixekizumab (Taltz). Called “” (see also here) the website promises that eligible patients could pay as little as $30 per month for both products ($5 for Taltz and $25 for Zepbound) if they are prescribed both medications.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with C.
Contact C., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack